|Videos|December 2, 2022
Shifting the Paradigm of Clinical Research in Alzheimer Disease With the COCOA Trial: Jared Roach, MD, PhD
Author(s)Jared Roach, MD, PhD
The senior research scientist at the Institute for Systems Biology spoke about changing the perception of clinical trials for Alzheimer disease research based on the COCOA trial presented at the 2022 CTAD conference. [WATCH TIME: 2 minutes]
Advertisement
WATCH TIME: 2 minutes
“I think there are ways to increase data sharing where it's a win-win [situation]. One of the things we're doing by getting dense data on individuals, like in a cohort study, is we're learning a tremendous amount of biology and we're learning the nuances of what we're doing so that we can fine tune and personalize things.”
Presently, for individuals with Alzheimer disease (AD), there is a need for more interventional treatments that are effective. As lifestyle factors have been known to play a role in the incidence rate of AD, investigators such as Jared Roach, MD, and colleagues, suggest that research on AD should include several personalized interventions that would tailor to reducing the progression of AD.1
Roach and colleagues recently performed a randomized controlled trial with a developed multimodal intervention program that resulted in a 95% retention rate and a 86% compliance rate for patients with early AD.1 The program is an example of shifting the paradigm of clinical trial research for the prevention of cognitive decline based on lifestyle behaviors and how to explain the targeted biological systems at play.
Recently, at the 2022 Clinical Trials on Alzheimer Disease (CTAD) conference , held November 29 to December 2, in San Francisco, California, Roach, a senior research scientist at the Institute for Systems Biology, sat down with NeurologyLive® and spoke about the types of research that impact the clinical trial field, specifically with Alzheimer disease. He explained how his research has changed the perception of clinical trials and what the goal is going forward into future investigations.
REFERENCES
1. McEwen SC, Merrill DA, Bramen J, et al. A systems-biology clinical trial of a personalized multimodal lifestyle intervention for early Alzheimer's disease. Alzheimers Dement (N Y). 2021;7(1):e12191. Published 2021 Jul 20. doi:10.1002/trc2.12191
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4